Optimalisatie van de behandeling met cetuximab voor patienten met uitgezaaide dikkedarm kanker door de opname van 89-zirconium gelabeld cetuximab te beoordelen middels PET-sca
Recruiting
- Conditions
- Metastatic colorecal adenocarcinoma, K-RAS and N-RAS wild type.
- Registration Number
- NL-OMON26385
- Lead Sponsor
- VU University Medical Center (central site)UMC GroningenRadboud UMC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 85
Inclusion Criteria
• Advanced colorectal adenocarcinoma
• Subjects must have been treated according to standard care with palliative chemotherapy including a fluoropyrimidine (e.g. fluorouracil or capecitabine), irinotecan, and oxaliplatin or had contra-indications to treatment with these drugs.
Exclusion Criteria
• Previous exposure to an anti-EGFR therapy
• Significant skin condition interfering with treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 89Zr-cetuximab uptake in non-hepatic metastases (corrected VOIs) and the correlation with clinical benefit rate.<br><br /><br /><br>89Zr-cetuximab uptake in non-hepatic metastases with increased dosing of cetuximab (corrected VOIs).<br><br /><br /><br>The clinical benefit rate (CR, PR and SD) based upon 89Zr-cetuximab image adjusted dosing
- Secondary Outcome Measures
Name Time Method